Published in Blood Cells Mol Dis on September 13, 2005
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer (2009) 2.76
Isolation and characterization of RNA-containing exosomes. J Vis Exp (2012) 2.16
Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol (2011) 1.93
Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res (2011) 1.83
Senescence-associated exosome release from human prostate cancer cells. Cancer Res (2008) 1.78
Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med (2006) 1.63
Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet (2012) 1.60
Circulating miRNAs: cell-cell communication function? Front Genet (2013) 1.55
Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol (2013) 1.54
The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J (2007) 1.50
The Potential of HLA-G-Bearing Extracellular Vesicles as a Future Element in HLA-G Immune Biology. Front Immunol (2016) 1.45
Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem (2012) 1.40
Nanoparticle tracking analysis monitors microvesicle and exosome secretion from immune cells. Immunology (2012) 1.35
Role of exosomes in immune regulation. J Cell Mol Med (2006) 1.29
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One (2011) 1.28
Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics (2012) 1.26
Transfer of extracellular vesicles during immune cell-cell interactions. Immunol Rev (2013) 1.25
Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget (2014) 1.25
Exosome removal as a therapeutic adjuvant in cancer. J Transl Med (2012) 1.24
Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol (2015) 1.23
The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids. Front Genet (2013) 1.21
Oncogenic extracellular vesicles in brain tumor progression. Front Physiol (2012) 1.15
Identification of a conserved glycan signature for microvesicles. J Proteome Res (2011) 1.14
Exosomes and immune surveillance of neoplastic lesions: a review. Biotech Histochem (2012) 1.12
Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun Signal (2012) 1.08
Release of luminal exosomes contributes to TLR4-mediated epithelial antimicrobial defense. PLoS Pathog (2013) 1.01
Myotube-derived exosomal miRNAs downregulate Sirtuin1 in myoblasts during muscle cell differentiation. Cell Cycle (2013) 1.01
Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles (2013) 0.97
CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity. Cell Mol Immunol (2010) 0.97
Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One (2014) 0.97
The exosomes in tumor immunity. Oncoimmunology (2015) 0.92
Microvesicles as mediators of tissue regeneration. Transl Res (2013) 0.91
Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin Cancer Res (2013) 0.90
Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J Ovarian Res (2014) 0.88
Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol Immunother (2010) 0.87
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget (2015) 0.85
Exosome nanovesicles displaying G protein-coupled receptors for drug discovery. Int J Nanomedicine (2007) 0.85
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell (2016) 0.85
Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer (2013) 0.84
Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus-derived extracellular vesicles. EMBO Mol Med (2016) 0.83
Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment. Oncotarget (2016) 0.82
The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn (2015) 0.81
RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncoimmunology (2016) 0.79
Extracellular vesicle-mediated transfer of processed and functional RNY5 RNA. RNA (2015) 0.78
Protective Role for TWEAK/Fn14 in Regulating Acute Intestinal Inflammation and Colitis-Associated Tumorigenesis. Cancer Res (2016) 0.78
Extracellular vesicles in prostate cancer: new future clinical strategies? Biomed Res Int (2014) 0.78
Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway. J Neuroinflammation (2016) 0.77
Exosomes in carcinogenesis: molecular palkis carry signals for the regulation of cancer progression and metastasis. J Cell Commun Signal (2016) 0.77
Killer B lymphocytes and their fas ligand positive exosomes as inducers of immune tolerance. Front Immunol (2015) 0.77
The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt? Vaccines (Basel) (2015) 0.77
Functions of Cancer-Derived Extracellular Vesicles in Immunosuppression. Arch Immunol Ther Exp (Warsz) (2017) 0.76
CD4+VEGFR1(HIGH) T cell as a novel Treg subset regulates inflammatory bowel disease in lymphopenic mice. Cell Mol Immunol (2015) 0.76
Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.76
Texosome-based drug delivery system for cancer therapy: from past to present. Cancer Biol Med (2015) 0.76
Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response. Front Immunol (2017) 0.75
The discovery of HLA-G-bearing extracellular vesicles: new perspectives in HLA-G biology. Ann Transl Med (2017) 0.75
The role of exosomes contents on genetic and epigenetic alterations of recipient cancer cells. Iran J Basic Med Sci (2016) 0.75
Toll-like receptor 3-activated macrophages confer anti-HCV activity to hepatocytes through exosomes. FASEB J (2016) 0.75
The secretion and biological function of tumor suppressor maspin as an exosome cargo protein. Oncotarget (2017) 0.75
Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. Crit Rev Oncog (2015) 0.75
Oxygen-Related Differences in Cellular and Vesicular Phenotypes Observed for Ovarian Cell Cancer Lines. J Circ Biomark (2016) 0.75
Biodistribution, Uptake and Effects Caused by Cancer-Derived Extracellular Vesicles. J Circ Biomark (2015) 0.75
Tumor-derived exosomes induce CD8(+) T cell suppressors. J Immunother Cancer (2017) 0.75
CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases. Front Immunol (2017) 0.75
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Extremely efficient multiple electron-hole pair generation in carbon nanotube photodiodes. Science (2009) 1.91
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol (2007) 1.72
ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. Biochem Biophys Res Commun (2003) 1.70
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62
Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation (2009) 1.60
Current status of local salvage therapies following radiation failure for prostate cancer. J Urol (2005) 1.57
Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol (2010) 1.57
The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. Asia Pac J Clin Nutr (2005) 1.53
Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int (2006) 1.53
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J (2011) 1.49
Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44
Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41
Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer? BJU Int (2005) 1.41
Malignant melanoma in pigmented skin: does the current interventional model fit a different clinical, histologic, and molecular entity? Dermatol Surg (2013) 1.41
Ghrelin receptor as a novel imaging target for prostatic neoplasms. Prostate (2011) 1.40
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol (2009) 1.39
The Canadian Urology Fair: a model for minimizing the financial and academic costs of the residency selection process. Can J Surg (2003) 1.32
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int (2010) 1.31
Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology (2007) 1.29
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27
Encoding electronic properties by synthesis of axial modulation-doped silicon nanowires. Science (2005) 1.26
Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res (2013) 1.25
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int (2008) 1.23
Surgical margin status among men with organ-confined (pT2) prostate cancer: a population-based study. Can Urol Assoc J (2011) 1.17
Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res (2007) 1.16
microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep (2012) 1.15
Wafer scale homogeneous bilayer graphene films by chemical vapor deposition. Nano Lett (2010) 1.15
Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol (2008) 1.14
Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J (2009) 1.13
Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11
Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med (2009) 1.10
The complete exosome workflow solution: from isolation to characterization of RNA cargo. Biomed Res Int (2013) 1.10
Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol (2007) 1.10
Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med (2010) 1.09
Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res (2002) 1.09
In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol (2009) 1.08
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J (2011) 1.07
Flexible ureteroscopy and laser lithotripsy for bilateral multiple intrarenal stones: is this a valuable choice? Urology (2012) 1.07
Contemporary technique of intraoperative 3-dimensional ultrasonography-guided transperineal prostate cryotherapy. Can Urol Assoc J (2009) 1.07
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
NK cells induce apoptosis in tubular epithelial cells and contribute to renal ischemia-reperfusion injury. J Immunol (2008) 1.07
One-step direct transfer of pristine single-walled carbon nanotubes for functional nanoelectronics. Nano Lett (2010) 1.06
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
Fast detection of the metallic state of individual single-walled carbon nanotubes using a transient-absorption optical microscope. Phys Rev Lett (2010) 1.05
Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol (2006) 1.05
Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. Oligonucleotides (2009) 1.05
Detection beyond the Debye screening length in a high-frequency nanoelectronic biosensor. Nano Lett (2012) 1.05
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. Can Urol Assoc J (2009) 1.01
RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant (2004) 0.99
Superiority of the Bryan(®) disc prosthesis for cervical myelopathy: a randomized study with 3-year followup. Clin Orthop Relat Res (2011) 0.99
Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation (2006) 0.98
Involvement of actin rearrangements within the amygdala and the dorsal hippocampus in aversive memories of drug withdrawal in acute morphine-dependent rats. J Neurosci (2009) 0.98
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol (2010) 0.97
Cord blood in regenerative medicine: do we need immune suppression? J Transl Med (2007) 0.97
Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation (2006) 0.97
Flexible and transparent all-graphene circuits for quaternary digital modulations. Nat Commun (2012) 0.97
Transitional-cell carcinoma recurrence rate after nephroureterectomy in patients who undergo open excision of bladder cuff v transurethral incision of the ureteral orifice. J Endourol (2007) 0.97
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother (2009) 0.97
Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol (2010) 0.96
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic. J Transl Med (2013) 0.96
Extinction of aversive memories associated with morphine withdrawal requires ERK-mediated epigenetic regulation of brain-derived neurotrophic factor transcription in the rat ventromedial prefrontal cortex. J Neurosci (2012) 0.96
Tolerogenic dendritic cells transferring hyporesponsiveness and synergizing T regulatory cells in transplant tolerance. Int Immunol (2008) 0.95
Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol (2008) 0.95